Wai Chun Bio-Technology Ltd.

As of December 31, 2025, Wai Chun Bio-Technology Ltd. carries a market capitalization of 33.55M, placing it among publicly traded companies globally. Its enterprise value stands at 198.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Wai Chun Bio-Technology Ltd. has 178.48M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Wai Chun Bio-Technology Ltd. maintains a current ratio of 0.67, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 30, 2026, Wai Chun Bio-Technology Ltd.'s stock has gained approximately 143.98% over the past 52 weeks. The 50-day moving average sits at 0.44, while the 200-day moving average is 0.37.

As of December 31, 2025, Wai Chun Bio-Technology Ltd. holds 5.61M in cash and equivalents against 141.87M in total debt, resulting in a net debt position of 136.26M. Total book value stands at -63.76M, with working capital of -61.19M providing operational flexibility.

Wai Chun Bio-Technology Ltd.'s most recent stock split took place on March 30, 2023 with a 10:1 split ratio.